Moberg Pharma changes in Board of Directors

Moberg Pharma AB (OMX: MOB) announces that, effective as of today, George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012. Appointed by Altaris Capital Partners, George E. Aitken-Davies remains a member of the Nomination Committee of Moberg Pharma until the Annual General Meeting in May 2015.

I would like to thank George for his valuable contributions to the board at Moberg Pharma. The acquisition in 2012 of Moberg Pharma North America (previously Alterna LLC), a former portfolio company of Altaris Capital Partners, has been a success and today represents two thirds of the sales of Moberg Pharma,” said Peter Wolpert, CEO of Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 pm (CET) on November 14, 2014.

For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35

E-mail: peter.wolpert@mobergpharma.se   

Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe

Quotes

I would like to thank George for his valuable contributions to the board at Moberg Pharma. The acquisition in 2012 of Moberg Pharma North America (previously Alterna LLC), a former portfolio company of Altaris Capital Partners, has been a success and today represents two thirds of the sales of Moberg Pharma
Peter Wolpert, CEO of Moberg Pharma AB